Zsquare

About Zsquare

Zsquare Medical, an Israeli medical device company established in 2013, is focused on the development and commercialization of a single-use endoscopic platform. The company was co-founded by CEO Dr. Asaf Shahmoon and CTO Professor Zeev Zalevsky. Their backgrounds in science and technology are central to the company's foundation, which is built upon proprietary, patent-protected fiber-optic technology.

The company operates in the medical diagnostics equipment market, specifically targeting the growing demand for single-use devices to mitigate cross-contamination risks associated with reusable endoscopes. Zsquare's business model centers on a hybrid system composed of a reusable imaging core and disposable, indication-specific shells. This approach allows healthcare providers in hospitals and private practices to reduce per-procedure costs while maintaining high-quality imaging. Revenue is generated from the sale of these disposable components designed for various medical fields, including ENT, urology, gynecology, and bronchoscopy.

Zsquare's core product is its flexible endoscopic platform, which utilizes an ultra-thin polymeric imaging fiber. This technology enables the construction of endoscopes with very small diameters, such as the 2.3mm Zsquare ENT-Flex™ Rhinolaryngoscope, without compromising image resolution. A key feature is the modular design: a single, reusable imaging core can be paired with different sterile, single-use shells tailored for specific procedures. This design addresses several critical issues in endoscopy: it eliminates the need for costly and time-consuming sterilization, reduces patient discomfort due to the smaller instrument size, and provides clinicians with consistently high-performance imaging, thereby potentially improving diagnostic accuracy. The platform's scalability is a significant benefit, allowing for rapid adaptation to various medical specialties.

The company has achieved significant milestones, including securing a total of $25 million in funding over two rounds, with investments led by Chartered Group. A major achievement was receiving FDA 510(k) clearance in July 2022 to market its first product, the Zsquare ENT-Flex™ Rhinolaryngoscope, in the United States. This clearance paved the way for a planned pilot launch in U.S. hospitals and physician offices.